A Phase 2 Study of GPC-100 and Propranolol With and Without G-CSF in People With Multiple Myeloma Having an Autologous Stem Cell Transplant


Full Title

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC-100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant


Researchers want to see if the drugs GPC-100 and propranolol can improve stem cell collection before autologous stem cell transplant (ASCT). The people in this study have multiple myeloma and will be having ASCT as part of their care.

An ASCT replaces the blood-forming cells that have been destroyed by disease or cancer treatments. These cells are replaced with healthy cells (stem cells) collected from your own blood. To gather enough stem cells for ASCT, they need to be mobilized (pushed out) from the bone marrow into the bloodstream.

The usual method to mobilize stem cells is to give injections of G-CSF (granulocyte colony stimulating factor). GPC-100 helps stem cells travel from the bone marrow to the bloodstream.  Propranolol helps restore stem cell growth and function in the bone marrow.

Researchers will see how well the combination of GPC-100 and propranolol works to boost the amount of stem cells collected. If you join this study, you will randomly assigned to get GPC-100 and propranolol with or without G-CSF.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that will be treated with an ASCT.
  • Have completed any prior chemotherapy at least 4 weeks before the ASCT.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Gunjan Shah’s office at 646-608-3734.




Phase II (phase 2)

Disease Status

Newly Diagnosed



ClinicalTrials.gov ID